Immuneering Co. (NASDAQ:IMRX - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings estimates for shares of Immuneering in a research report issued on Monday, March 24th. Chardan Capital analyst G. Livshits anticipates that the company will post earnings of ($1.65) per share for the year. Chardan Capital currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Immuneering's current full-year earnings is ($1.86) per share.
A number of other analysts have also recently weighed in on IMRX. Morgan Stanley cut Immuneering from an "equal weight" rating to an "underweight" rating in a research report on Friday, December 13th. Needham & Company LLC restated a "buy" rating and set a $12.00 price target on shares of Immuneering in a research report on Friday, March 21st.
Read Our Latest Analysis on Immuneering
Immuneering Trading Down 0.3 %
IMRX traded down $0.01 on Thursday, hitting $1.64. 37,990 shares of the company's stock were exchanged, compared to its average volume of 1,776,107. The stock has a fifty day moving average of $1.76 and a two-hundred day moving average of $2.02. Immuneering has a twelve month low of $1.00 and a twelve month high of $3.83. The firm has a market cap of $58.68 million, a PE ratio of -0.83 and a beta of -0.32.
Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.16).
Institutional Trading of Immuneering
Several hedge funds have recently added to or reduced their stakes in the business. Corsair Capital Management L.P. acquired a new position in shares of Immuneering during the third quarter valued at $25,000. HighTower Advisors LLC grew its position in Immuneering by 21.4% in the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company's stock valued at $132,000 after buying an additional 9,400 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new position in Immuneering during the 4th quarter valued at about $390,000. XTX Topco Ltd raised its position in shares of Immuneering by 177.2% during the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock worth $72,000 after buying an additional 20,871 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Immuneering in the 4th quarter worth approximately $47,000. Institutional investors own 67.65% of the company's stock.
About Immuneering
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Read More
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
